As highlighted in the WDOM’s 2021 Annual Report, Dr. S. Louis “Lou” Bridges, Jr., Chief, Division of Rheumatology, WDOM, remains focused on optimizing new approaches in clinical research and mentoring.
The study employed a sophisticated computer modeling platform built in response to the COVID-19 pandemic.
Dr. Cristofanilli's many scientific advances in the field of breast cancer include novel biomarkers (endocrine), findings on circulating tumor cells, and drug development with a focus on endocrine therapy.
The award will support Dr. Landau’s development of novel technology to study clonal mosaicism in normal tissues. This research will open a critical window into the earliest stages of cancer formation.
The research suggests that countering the activity of inflammatory ILC3s could lead to a therapeutic approach for multiple sclerosis and other brain disorders.
These findings have opened a window into the development of inflammatory bowel disease (IBD), as well as insights into a rare syndrome in which the SATB2 gene is disrupted.
Lectures were provided by WDOM faculty and keynote speaker, Dr. Drew Weissman, who played a major role in critical discoveries that allowed for the mRNA platform to be used in developing vaccines against SARS-CoV.
The researchers found that SARS-CoV-2 triggers an inflammatory antiviral response in the adipose tissue (body fat) and causes its dysfunction.
The new Center is well-positioned to become a world-renowned leader for scientific discovery in translational and molecular discovery related to the pathogenesis and treatment of metabolic disease.
With more than 200 pulmonary disorders that fall under the umbrella of ILD, patient evaluation, proper diagnosis, and determining the best treatment is of the utmost importance.
